Communiqués SOPHiA GENETICS SA Börse Stuttgart

Actions

90B

CH1125843347

Equipement et technologie médicale avancés

Temps réel estimé Tradegate 21:51:42 11/09/2026			Varia. 5j.	Varia. 1 janv.
6,700 ^EUR	+3,08 %		-5,04 %	+70,10 %

04/08	Transcript : SOPHiA GENETICS SA, Q2 2026 Earnings Call, Aug 04, 2026
04/08	Sophia Genetics SA et AstraZeneca concluent une collaboration pour développer des diagnostics compagnons en oncologie de précision	CI

Communiqués

04/08	SOPHiA GENETICS Reports Second Quarter 2026 Results	PR
04/08	SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies	AQ
21/07	SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026	PR
22/06	SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting	PR
19/06	SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares	PR
17/06	SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares	PR
16/06	SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares	PR
10/06	SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting	AQ
04/06	SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center	PR
01/06	SOPHiA GENETICS : and ARC Regulatory Collaborate to Support EU Clinical Trial Assay Development	PU
13/05	Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.	AQ
05/05	SOPHiA GENETICS Reports First Quarter 2026 Results	PR
21/04	SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026	PR
16/04	Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026	AQ
03/03	SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results	PR
25/02	SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference	PR
17/02	SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026	PR
10/02	SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems	PR
10/02	SOPHiA GENETICS : AZ Delta Roeselare Joins the SOPHiA GENETICS Community	PU
12/01	SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan	PR
07/01	SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology	PR
18/12	SOPHiA GENETICS : Advancing Hereditary Cancer Research in Mexico	PU
16/12	SOPHiA GENETICS : Expanding Precision Oncology Research in England	PU
05/12	SOPHiA GENETICS : Tyrolpath Adopts MSK-IMPACT®-Flex powered with SOPHiA DDM™ to Expand Precision Oncology in Austria	PU
28/11	SOPHiA GENETICS : Expanding Precision Medicine in Mexico with Genos Médica	PU